Home  |  Contact

UniProtKB/Swiss-Prot P06213: Variant p.Val1054Met

Insulin receptor
Gene: INSR
Variant information

Variant position:  1054
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Unclassified
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Valine (V) to Methionine (M) at position 1054 (V1054M, p.Val1054Met).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Insulin-resistant diabetes mellitus with acanthosis nigricans type A (IRAN type A) [MIM:610549]: Characterized by the association of severe insulin resistance (manifested by marked hyperinsulinemia and a failure to respond to exogenous insulin) with the skin lesion acanthosis nigricans and ovarian hyperandrogenism in adolescent female subjects. Women frequently present with hirsutism, acne, amenorrhea or oligomenorrhea, and virilization. This syndrome is different from the type B that has been demonstrated to be secondary to the presence of circulating autoantibodies against the insulin receptor. {ECO:0000269|PubMed:10733238, ECO:0000269|PubMed:11260230, ECO:0000269|PubMed:12107746, ECO:0000269|PubMed:12970295, ECO:0000269|PubMed:1563582, ECO:0000269|PubMed:1963473, ECO:0000269|PubMed:2002058, ECO:0000269|PubMed:2168397, ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:2544998, ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:3283938, ECO:0000269|PubMed:8243830, ECO:0000269|PubMed:8288049, ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8388389, ECO:0000269|PubMed:9175790}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In IRAN type A; unknown pathological significance.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  1054
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1382
The length of the canonical sequence.

Location on the sequence:   FGMVYEGNARDIIKGEAETR  V AVKTVNESASLRERIEFLNE
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         FGMVYEGNARDIIK--GEAETRVAVKTVNESASLRERIEFLNE

Mouse                         FGMVYEGNAKDIIK--GEAETRVAVKTVNESASLRERIEFL

Rat                           FGMVYEGNAKDIIK--GEVETRVAVKTVNESASLRERIEFL

Xenopus laevis                FGMVYEGIAKDIIK--GEPEVRVAVKTVNESASLRERIEFL

Caenorhabditis elegans        FGKVYLGTGNNVVSLMGDRFGPCAIKINVDDPASTENLNYL

Drosophila                    FGMVYEGILKSFPP--NGVDRECAIKTVNENATDRERTNFL

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 763 – 1382 Insulin receptor subunit beta
Topological domain 980 – 1382 Cytoplasmic
Domain 1023 – 1298 Protein kinase
Binding site 1057 – 1057 ATP
Mutagenesis 1057 – 1057 K -> A. Abolishes the kinase activity and abolishes interaction with IRS1, SHC1, GRB7 and PIK3R1.
Mutagenesis 1057 – 1057 K -> MR. Abolishes the kinase activity.
Beta strand 1050 – 1057


Literature citations

Structural Basis and Genotype-Phenotype Correlations of INSR Mutations Causing Severe Insulin Resistance.
Hosoe J.; Kadowaki H.; Miya F.; Aizu K.; Kawamura T.; Miyata I.; Satomura K.; Ito T.; Hara K.; Tanaka M.; Ishiura H.; Tsuji S.; Suzuki K.; Takakura M.; Boroevich K.A.; Tsunoda T.; Yamauchi T.; Shojima N.; Kadowaki T.;
Diabetes 66:2713-2723(2017)
Cited for: VARIANTS RMS CYS-256; LEU-635; ILE-835; VAL-842; LEU-874; SER-878 AND 999-TYR--SER-1382 DEL; VARIANTS IRAN TYPE A ASP-489 AND MET-1054; VARIANTS LEPRCH PHE-657; ARG-659 AND CYS-818; CHARACTERIZATION OF VARIANTS LEPRCH PHE-657; ARG-659; CYS-818; THR-925; TRP-926 AND MET-937; CHARACTERIZATION OF VARIANTS RMS LEU-635; ILE-835; VAL-842; LEU-874 AND SER-878;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.